| Understanding LAG-3 signaling L Chocarro, E Blanco, M Zuazo, H Arasanz, A Bocanegra, ... International journal of molecular sciences 22 (10), 5282, 2021 | 124 | 2021 |
| Resistance to PD-L1/PD-1 blockade immunotherapy. A tumor-intrinsic or tumor-extrinsic phenomenon? L Chocarro de Erauso, M Zuazo, H Arasanz, A Bocanegra, C Hernandez, ... Frontiers in pharmacology 11, 441, 2020 | 63 | 2020 |
| Clinical landscape of LAG-3-targeted therapy L Chocarro, E Blanco, H Arasanz, L Fernández-Rubio, A Bocanegra, ... Immuno-Oncology and Technology 14, 100079, 2022 | 59 | 2022 |
| Systemic CD4 immunity as a key contributor to PD-L1/PD-1 blockade immunotherapy efficacy M Zuazo, H Arasanz, A Bocanegra, G Fernandez, L Chocarro, R Vera, ... Frontiers in Immunology 11, 586907, 2020 | 58 | 2020 |
| Cutting-edge: Preclinical and clinical development of the first approved lag-3 inhibitor L Chocarro, A Bocanegra, E Blanco, L Fernández-Rubio, H Arasanz, ... Cells 11 (15), 2351, 2022 | 43 | 2022 |
| Systemic blood immune cell populations as biomarkers for the outcome of immune checkpoint inhibitor therapies C Hernandez, H Arasanz, L Chocarro, A Bocanegra, M Zuazo, ... International journal of molecular sciences 21 (7), 2411, 2020 | 32 | 2020 |
| Circulating low density neutrophils are associated with resistance to first line anti-PD1/PDL1 immunotherapy in non-small cell lung cancer H Arasanz, AI Bocanegra, I Morilla, J Fernández-Irigoyen, ... Cancers 14 (16), 3846, 2022 | 29 | 2022 |
| Hyperprogressive disease: main features and key controversies H Arasanz, M Zuazo, A Bocanegra, L Chocarro, E Blanco, M Martínez, ... International journal of molecular sciences 22 (7), 3736, 2021 | 26 | 2021 |
| mRNA vaccines against SARS-CoV-2: Advantages and caveats M Echaide, L Chocarro de Erauso, A Bocanegra, E Blanco, G Kochan, ... International Journal of Molecular Sciences 24 (6), 5944, 2023 | 25 | 2023 |
| Systemic CD4 immunity: A powerful clinical biomarker for PD‐L1/PD‐1 immunotherapy M Zuazo, H Arasanz, A Bocanegra, L Chocarro, R Vera, D Escors, ... EMBO molecular medicine 12 (9), e12706, 2020 | 25 | 2020 |
| The multi-specific VH-based Humabody CB213 co-targets PD1 and LAG3 on T cells to promote anti-tumour activity CJ Edwards, A Sette, C Cox, B Di Fiore, C Wyre, D Sydoruk, D Yadin, ... British journal of cancer 126 (8), 1168-1177, 2022 | 15 | 2022 |
| CAR-T cells for the treatment of lung cancer L Chocarro, H Arasanz, L Fernández-Rubio, E Blanco, M Echaide, ... Life 12 (4), 561, 2022 | 14 | 2022 |
| Potent clinical predictive and systemic adjuvant therapeutic value of plasma fractalkine in PD-L1/PD-1 blockade immunotherapy for lung cancer A Bocanegra, G Fernández, D Ajona, H Arasanz, E Blanco, M Zuazo, ... MedRxiv, 2022.06. 16.22276511, 2022 | 13 | 2022 |
| Systemic CD4 immunity and PD-L1/PD-1 blockade immunotherapy D Escors, A Bocanegra, L Chocarro, E Blanco, S Piñeiro-Hermida, ... International Journal of Molecular Sciences 23 (21), 13241, 2022 | 12 | 2022 |
| Immune profiling uncovers memory T-cell responses with a Th17 signature in cancer patients with previous SARS-CoV-2 infection followed by mRNA vaccination M Echaide, I Labiano, M Delgado, A Fernández de Lascoiti, P Ochoa, ... Cancers 14 (18), 4464, 2022 | 10 | 2022 |
| How can we improve the vaccination response in older people? Part II: targeting immunosenescence of adaptive immunity cells M Garnica, A Aiello, ME Ligotti, G Accardi, H Arasanz, A Bocanegra, ... International Journal of Molecular Sciences 23 (17), 9797, 2022 | 10 | 2022 |
| A proteomic atlas of lineage and cancer-polarized expression modules in myeloid cells modeling immunosuppressive tumor-infiltrating subsets E Blanco, M Ibañez-Vea, C Hernandez, L Drici, X Martínez de Morentin, ... Journal of Personalized Medicine 11 (6), 542, 2021 | 9 | 2021 |
| Leading edge: intratumor delivery of monoclonal antibodies for the treatment of solid tumors E Blanco, L Chocarro, L Fernández-Rubio, A Bocanegra, H Arasanz, ... International Journal of Molecular Sciences 24 (3), 2676, 2023 | 7 | 2023 |
| Local delivery of optimized nanobodies targeting the PD-1/PD-L1 axis with a self-amplifying RNA viral vector induces potent antitumor responses N Silva-Pilipich, E Blanco, T Lozano, E Martisova, A Igea, ... Cancer Letters 561, 216139, 2023 | 6 | 2023 |
| LAMC2 regulates key transcriptional and targetable effectors to support pancreatic cancer growth O Erice, S Narayanan, I Feliu, R Entrialgo-Cadierno, A Malinova, ... Clinical Cancer Research 29 (6), 1137-1154, 2023 | 6 | 2023 |
